Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical
stage vaccine company, today announced the results of the Company's Annual
General Meeting (AGM) of shareholders held on April 30, 2013. 


During the AGM, the shareholders re-elected Wade K. Dawe, James W. Hall,
Stephanie Leouzon, Wayne Pisano, Bradley Thompson, Ph.D., John J. Trizzino and
Albert Scardino to serve on the board of directors until the next annual meeting
of shareholders. Mr. Scardino will also continue his duties as non-executive
chairman of the board. Former director William A. Cochrane, M.D., did not stand
for re-election.


"The Board and management wish to thank Dr. Cochrane for his service and
contributions to the Board," said Mr. Scardino.


The shareholders approved all motions put forth at the meeting including the
appointment of PriceWaterhouseCoopers LLP, Chartered Accountants, as the
Company's independent auditors.


Immunovaccine Stock Option Plan

Immunovaccine today announced that its board of directors has approved certain
modifications to the Company's stock option plan. Specifically, the number of
Immunovaccine common shares reserved for issuance under the plan will increase
from 6,250,000 to 6,750,000. These modifications are subject to approval by the
TSX Venture Exchange.


Pursuant to terms and conditions of the Company's stock option plan,
Immunovaccine also announced that it has granted 514,070 stock options to
employees, consultants and directors. Employees and consultants were granted an
aggregate of 244,070 options, while directors were granted an aggregate of
270,000 options. The options, granted on April 30, 2013, have an exercise price
of $0.28 and will vest in three equal tranches at six, 12, and 18 months from
date of grant. The options are set to expire five years from the date of grant.


About Immunovaccine

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax(TM)-based cancer vaccines into
Phase I human clinical trials. The Company is also advancing a broad infectious
diseases pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Zoetis (formerly Pfizer Animal Health). Connect at
www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Kimberly Stephens
CFO
(902) 492-1819
info@imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com


Brisco Capital Partners (Canadian investors)
Scott Koyich
(403) 262-9888
skoyich@briscocapital.com